Form 8-K - Current report:
SEC Accession No. 0001012975-26-000195
Filing Date
2026-02-20
Accepted
2026-02-20 16:26:58
Documents
12
Period of Report
2026-02-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ormp-20260219.htm   iXBRL 8-K 66949
2 EX-10.1 ormp-ex10_1.htm EX-10.1 209904
3 EX-10.2 ormp-ex10_2.htm EX-10.2 287162
  Complete submission text file 0001012975-26-000195.txt   756649

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ormp-20260219.xsd EX-101.SCH 25951
14 EXTRACTED XBRL INSTANCE DOCUMENT ormp-20260219_htm.xml XML 4712
Mailing Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 646-844-1164
ORAMED PHARMACEUTICALS INC. (Filer) CIK: 0001176309 (see all company filings)

EIN.: 980376008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35813 | Film No.: 26660328
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)